OraLabs
This article was originally published in The Rose Sheet
Executive Summary
Third quarter revenues fell nearly 4% to $2.8 mil., a loss of $.08 per share, while net loss was $360,205, compared to net income of $33,431 in 2003. Parker, Colo. firm attributes lackluster results to expenses associated with the company's relocation, which contributed to reduced gross profit and a reported loss. OraLabs remains optimistic, noting, "the company is going into its busy season and we are hopeful that our expansion investments will pay off." OraLabs manufacturers lip care products such as ChapIce, Chap Grip and Soothe & Shine, as well as Ice Drops breath drops and sprays...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.